Based on the abnormal expression of DOK2 in digestive tract tumors such as gastric and colorectal cancers, some researchers established a prognostic evaluation model including DOK2 that effectively identified patients with poor prognosis [36, 37]. This evidence concerns the gene DOK2 and colorectal cancer.